BSX · CIK 885725
What Boston Scientific Corporation told the SEC could break it.
Boston Scientific's flagged risks are mostly external pressures on a global device maker rather than any internal concentration. The dominant one is pricing: cost-containment initiatives and healthcare reforms across the U.S., China, Australia, and Japan — health-technology assessments, price regulation, and competitive bidding or tendering — could cap the prices or reimbursement for its products. The rest is geographic. Its supply chain can face constraints on the raw materials and components it needs, raising costs or limiting its ability to meet demand, and its 13 principal manufacturing facilities span the U.S. and Puerto Rico, Ireland, Costa Rica, Malaysia, and China — a footprint exposed to geopolitical disruption from the Russia-Ukraine war, Taiwan Strait tension, and proliferating sanctions and export restrictions.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- geopolitical disruption — Russia/Ukraine, Taiwan strait, Middle East; sanctions/export restrictionslow
Geopolitical conflicts (Russia/Ukraine war, Taiwan strait tension, Middle East conflicts) and proliferating sanctions and export restrictions may disrupt Boston Scientific's global/regional markets, supply chains and operations, with the Russia/Ukraine war already creating barriers to doing business in Russia and parts of Eastern Europe.
“may cause disruptions to global or regional markets, supply chains or operations in applicable regions, including those related to the Russia/Ukraine war, tension in the Taiwan strait, and conflicts in the Middle East. Sanctions and export restrictions may continue to proliferate”
SEC filing →As of 2026 - manufacturing concentrated in US/Puerto Rico, Ireland, Costa Rica, Malaysia, Chinalow
Boston Scientific operated 13 principal manufacturing facilities at year-end 2025 — six in the U.S. and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia and one in China — concentrating production across a handful of countries.
“we maintained 13 principal manufacturing facilities, including six in the U.S. and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia, one in China”
Regulatory & policy
- healthcare cost-containment/reimbursement reforms (U.S., China, Australia, Japan); HTA, competitive bidding/tenderingmedium
Cost-containment initiatives and healthcare reforms in major markets (U.S., China, Australia, Japan) — including Health Technology Assessment determinations, price regulation, competitive bidding/tendering, and coverage/payment policy changes — may limit prices or reimbursement for Boston Scientific's products and procedures.
“Implementation of cost containment initiatives and health care reforms in significant markets such as the U.S., China, Australia, and other markets may limit the price of, or the level at which reimbursement is provided for, our products or procedures using our products”
SEC filing →As of 2026
Supplier concentration
- raw material and component supply-chain access affecting cost and ability to meet demandmedium
Constraints on Boston Scientific's access to needed raw materials and components could increase its costs or leave it unable to fully meet customer demand for certain products.
“ccess to the raw materials and components that we need, these supply chain dynamics could result in increased costs to us or an inability to fully meet customer demand for certain of our products.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Under the terms of the Merger Agreement, subject to the terms and conditions set forth in the Merger Agreement, our stockholders will have the right to elect, for each share of our common stock held by them, to receive $374 in cash or 3.8721 shares of Boston Scientific Corporation's common stock... The Merger is expected to close by the end of 2026, subject to customary closing conditions, including approval by our stockholders and regulatory approvals.”
Cited →
Its suppliers
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch